Connective tissue diseases reported in patients receiving immune checkpoint inhibitorsMarch 3, 2017Patient & Survivor CareImmunotherapyMelanomaImmuno-oncology
Vaccine + chemo induce robust T-cell responses in late-stage cervical cancerMarch 1, 2017Gynecologic CancerImmuno-oncology
Genomic differences seen in mRCC during first- and second-line therapyFebruary 28, 2017Genitourinary CancerRenal Cell CarcinomaImmuno-oncology
Pembrolizumab ‘new standard of care’ in advanced PD-L1-rich NSCLCOctober 17, 2016Lung CancerImmuno-oncology
Pembrolizumab boosts response but not survival in small study of advanced NSCLCOctober 13, 2016Lung CancerImmuno-oncology
Glimmer of promise for nivolumab in neoadjuvant NSCLC therapyOctober 7, 2016Lung CancerImmuno-oncology
Gene profile predicts RCC response to nivolumabAugust 4, 2016Genitourinary CancerImmuno-oncologyRenal Cell Carcinoma
SU2C announces researcher-industry collaboration on immunotherapyJuly 13, 2016Genitourinary CancerHead & Neck/Thyroid CancersMelanomaImmuno-oncologyRenal Cell Carcinoma
Immunosuppressive regimens did not affect risk of cancer recurrence in meta-analysisJuly 1, 2016GastroenterologyImmuno-oncologyGastrointestinal Cancer
Pembrolizumab paired with immunostimulator is safe and tolerableJune 15, 2016Genitourinary CancerHead & Neck/Thyroid CancersLung CancerImmuno-oncology
Neoadjuvant chemo for advanced ovarian cancer opens ‘window of opportunity’ for immunotherapiesJune 15, 2016Gynecologic CancerImmuno-oncology
